Does reducing albuminuria afford cardiovascular protection in patients with type 2 diabetic nephropathy?
Albuminuria reduction is highlighted as a therapeutic target for cardiovascular protection in type 2 diabetic nephropathy.
Albuminuria is an important factor predicting cardiovascular risk in patients with type 2 diabetic nephropathy. Reducing albuminuria in the first 6 months appears to afford cardiovascular protection in these patients.
Zeeuw et al. (Tue,) studied this question.